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Introduction {#sec005}
============

The recent shortage of intravenous opioids triggered by unanticipated manufacturing delays and increasingly restrictive federal drug policy resulted in anesthesia providers managing patients with critically low supplies of intravenous opioids. \[[@pone.0234199.ref001], [@pone.0234199.ref002]\] Alternate approaches to managing this parenteral opioid shortage included increased utilization of oral opioids, use of transdermal fentanyl and addition of nonopioid adjuncts to hospital formularies. \[[@pone.0234199.ref001], [@pone.0234199.ref003]\]

In contrast to the impact of an oral opioid substitution protocol in a nonsurgical cohort, there is limited data on the impact of limited parenteral opioids on pain management during and after a surgical intervention. \[[@pone.0234199.ref004]\] We present our data over a 23-month period (9 months pre-intervention and 14 months post-intervention) following institution of a guideline developed by our Acute Pain Service and the Inpatient Pharmacy in response to the acute, limited supply of parenteral opioids. The goals of the protocol were to create an intravenous to oral opioid substitution guideline for intraoperative and immediate postoperative pain management, facilitate increase use of nonopioid analgesia and ensure that neuraxial and loco-regional techniques were utilized when appropriate. We hypothesize that adoption of this new guideline was associated with: 1) equivalent patient reported pain scores in the post anesthesia care unit (PACU); and 2) equivalent total opioid use (oral and parenteral) during the perioperative period.

Methods {#sec006}
=======

Study design {#sec007}
------------

We performed a single center, interrupted time series with segmented regression analysis investigating opioid, nonopioid, loco-regional and neuraxial utilization at the University of Virginia prior to and following implementation of protocol designed to limit intravenous opioid use.

### Ethics statement {#sec008}

The institutional review board at the University of Virginia waived the requirement for written informed consent and approved the study. The study approval number is HSR \#21976. Data was not anonymized before accessing it. The source of the medical records analyzed in this work were obtained only from the University of Virginia Health Center. The STROBE statement checklist for reporting observational studies was followed throughout this study and reported in the [S1 Checklist](#pone.0234199.s001){ref-type="supplementary-material"}.

Study population {#sec009}
----------------

All cases documented in our electronic medical record from July 1, 2017 to May 31, 2019 were initially screened. The new guideline was implemented on April 1, 2018. We excluded cases that were performed on patients \< 18 years, American Society of Anesthesiologist (ASA) Physical Status 5 and 6 patients, those without recorded PACU pain scores within 2 hours after surgery, patients undergoing cardiac surgery and those who remained intubated postoperatively.

Study intervention {#sec010}
------------------

The Limited Intravenous Opioid Guideline, described below, was developed in collaboration with the Acute Pain Service and the Pharmacy Department. Prior to implementation of the protocol, a meeting with all stakeholders (anesthesia providers, surgeons, pharmacy, preoperative and postoperative nursing staff) were held and active feedback was solicited. The final protocol was approved by all stakeholders prior to the implementation date.

### Limited intravenous opioid guideline {#sec011}

The guideline was anchored by the following principles: 1) Increase use of multimodal, nonopioid adjuvants prior to surgery, during the procedure and in the PACU, 2) Use of short and long acting enteral and rectal opioids prior to surgery, during the procedure and in the PACU, 3) The use of loco-regional and neuraxial techniques, when appropriate. These components were implemented through the three major perioperative phases of care:: pre-operatively, intraoperatively, and in PACU. The choice and combination of analgesic agents utilized were left at the discretion of the anesthesia providers.

Preoperative phase of care (surgical admissions suite) {#sec012}
------------------------------------------------------

**1. Non-opioids.** Unless contraindicated, all patients with an anticipated postoperative in-patient admission and with a surgical duration greater than 2 hours received the following nonopioid analgesics orally: gabapentin 600 mg, celecoxib 200 mg and acetaminophen 975 mg. If the expected surgical duration was less than 2 hours or patients were planned to be discharged after the procedure, they received the aforementioned combination of nonopioid analgesics however gabapentin was reduced to 300 mg.

**2. Opioids.** Oral opioids were administered prior the procedure based on the expected duration of surgery and the postoperative destination status (in-patient requiring admission vs. outpatient being discharged on the day of procedure)

Procedures less than two hours and/or outpatient status {#sec013}
-------------------------------------------------------

a.  Oxycodone 5 mg-10 mg or hydromorphone 2--4 mg orally.

Procedures greater than two hours and/or inpatient status {#sec014}
---------------------------------------------------------

a.  Methadone 5--10 mg orally or

b.  Extended release morphine 15--30 mg orally or

c.  Extended release oxycodone 10--20 mg orally

d.  Patients undergoing cardiac or complex spine surgery received higher doses of oral methadone (0.2 to 0.3 mg/kg).

Intraoperative Phase of Care:

1.  Use of esmolol bolus (10--50 mg) to blunt intubation response with avoidance of intravenous opioids

2.  Intravenous ketamine infusions 0.1--0.3 mg/kg/hour, if not contraindicated

3.  Intravenous lidocaine infusions ranging from 1--3.5 mg/min, if not contraindicated

4.  Intravenous dexmedetomidine 0.3--0.7 mcg/kg/h, if not contraindicated.

5.  The use of nonsteroidal anti-inflammatory agents (ketorolac 15--30 mg) after discussion with the surgical team and if no celecoxib was administered preoperatively.

6.  Use of morphine suppository (10--20 mg), 30--60 minutes prior to the end of the case if patient demonstrated features of inadequate analgesia such as persistent hypertension and tachycardia.

7.  The use of loco-regional techniques when appropriate at the end of cases (e.g. transversus abdominus plane and rectus sheath blocks)

8.  Intravenous fentanyl or hydromorphone, after approval from the attending anesthesiologist, if aforementioned interventions contra-indicated or not effective in providing analgesia (persistent hypertension and tachycardia)

PACU Phase of Care:

1.  For acute postoperative pain: oral oxycodone 5--10 mg or oral hydromorphone 2--4 mg with or without acetaminophen 975 mg (if timing appropriate from preoperative phase of care dose). Where appropriate, repeated dose of nonsteroidal anti-inflammatory agents was encouraged.

2.  At the discretion of the anesthesia provider, continuation of the lidocaine infusions at 0.5--1 mg/min or ketamine infusions at 0.1 mg/kg/hour.

3.  For acute severe postoperative pain: administration of intravenous fentanyl or hydromorphone, after approval from the attending anesthesiologist. Addition of ketamine 20 mg intravenous once (with accompanying midazolam as needed).

Data variables {#sec015}
--------------

Demographic data collected included age, gender, height and weight. ASA physical status, surgical case type and case length (start of case to end of case) were recorded. ASA physical status, case length and surgical case type were used as a surrogate for case complexity.

Non-opioid medications including acetaminophen, celecoxib, dexmedetomidine, esmolol, gabapentin, ketamine and lidocaine administered preoperatively, intraoperatively and postoperatively in the PACU were recorded. Data for any loco-regional or neuraxial procedures performed either pre, intra or postoperatively in the PACU were collected.

Study outcomes {#sec016}
--------------

All pre, intra and postoperative opioids including fentanyl, sufentanil, alfentanil, morphine, hydromorphone, meperidine, remifentanil, methadone, tramadol and oxycodone were recorded. Opioid doses administered with either epidural or spinal anesthesia prior to the procedure were also included. All opioids administered via the oral, parenteral, or neuraxial route were converted to intravenous morphine equivalent (ME) dose using a standardized dose calculator([http://www.uptodate.com/contents/cancerpainmanagement-with-opioids optimizing-analgesia](http://www.uptodate.com/contents/cancerpainmanagement-with-opioids%20optimizing-analgesia)). Mean and median ME per case were calculated for each calendar month from July 2017 to May 2019.

All PACU patient-reported pain score (11-point numerical score) recorded by the nursing team were averaged per case. Mean and median pain scores for each calendar month from July, 2017 to May 2019 were calculated.

Sample size {#sec017}
-----------

This was a convenience sample of all eligible cases that could be included during the study period from July, 2017 to May, 2019.

Statistical analysis {#sec018}
--------------------

For continuous variables, descriptive statistics of cases are presented as mean, standard deviation, minimum, and maximum. For categorical variables, the number of cases in each category are presented. Chi-square tests were used to compare categorical variables (gender, ASA) and linear regression models were used to compare continuous variables (age, height, weight, BMI, case length). All tests were 2-sided and P value \< 0.05 was considered to be statistically significant.

Segmented regression analyses of interrupted time series were performed examining the change in morphine equivalent per case (total, parenteral and enteral), PACU pain scores and number of non-opioid analgesic medications used before and after the intervention in April, 2018 was performed. The segmented regression analysis accounts for changes in level (for an abrupt intervention effect) and trend (increase or decrease in the slope) that follow an intervention and estimates the levels and trends separately for pre- and postintervention segments. \[[@pone.0234199.ref005]\] Descriptive statistics and regression models were performed in R (version 3.3.2). The segmented time-series regression analyses were performed in SPSS (version 24).

Results {#sec019}
=======

A total of 56, 451 cases were identified during the study period. After exclusions 29, 621 patients were included in the final analysis ([Fig 1](#pone.0234199.g001){ref-type="fig"}). Demographic data including sex, height and weight and PACU length of stay were not significantly different between the pre and post-intervention group ([Table 1](#pone.0234199.t001){ref-type="table"}). Age was significantly different in the pre and post intervention period however the point estimate difference was only 0.61 years. Although there was a statistically significant difference in case length between the pre and post-intervention period (Pre intervention: 146 ± 108 minutes, Post intervention: 141 ± 113 minutes, p \< 0.001) the mean point difference was only 4.5 minutes. ASA physical status ([Table 1](#pone.0234199.t001){ref-type="table"}, [S1 Fig](#pone.0234199.s002){ref-type="supplementary-material"}) and surgical procedure type ([Fig 2](#pone.0234199.g002){ref-type="fig"}) were similar in the pre and post-intervention period.

![Flow diagram of study participant selection.](pone.0234199.g001){#pone.0234199.g001}

![Proportion of surgical procedures over time.](pone.0234199.g002){#pone.0234199.g002}

10.1371/journal.pone.0234199.t001

###### Demographic, ASA physical status and case length in the pre and post-intervention group.

![](pone.0234199.t001){#pone.0234199.t001g}

  Variable                  Pre-Intervention                                 Post-Intervention                                Estimate or (*X*^2^)   Standard Error or (*df*)   *t*     *p*
  ------------------------- ------------------------------------------------ ------------------------------------------------ ---------------------- -------------------------- ------- ----------
  Age                       57.2 ± 16.1 (median = 59, range = 18--100)       57.8 ± 16.0 (median = 60, range = 18--97)        -0.61                  0.19                       -3.20   \<0.01
  Height (in)               66.9 ± 4.2 (median = 67, range = 32--82)         67.0 ± 4.2 (median = 67, range = 43--84)         -0.02                  0.05                       -0.34   0.74
  Gender (Female) (%)       52.8                                             52.3                                             (0.85)                 \(1\)                              0.36
  Weight (kg)               87.1 ± 23.4 (median = 84.1, range = 40--199.4)   87.4 ± 23.4 (median = 84.4, 40--200)             -0.31                  0.29                       -1.06   0.29
  BMI                       30.1 ± 7.6 (median = 28.9, range = 13.7--75.5)   30.3 ± 7.7 (median = 29.1, range = 13.8--75.9)   -0.15                  0.10                       -1.50   0.13
  Case Length               145.8 ± 108.5 (median = 117, range = 10--715)    141.3 ± 108.5 (median = 111, range = 10--717)    4.49                   1.33                       3.39    \< 0.001
  ASA Physical Status (%)                                                                                                                                                               
  1                         4.7                                              4.3                                              (5.9)                  \(5\)                              0.32
  2                         39.8                                             39.8                                                                                                       
  3                         45.7                                             45.4                                                                                                       
  4                         8.9                                              9.6                                                                                                        
  5                         0.2                                              0.2                                                                                                        
  6                         0.04                                             0.02                                                                                                       
  Missing                   0.6                                              0.8                                                                                                        

Chi-square tests were used to compare categorical variables (gender, ASA) and linear regression models were used to compare continuous variables (age, height, weight, BMI, case length). *df*: degrees of freedom; ASA: American Society of Anesthesiologist; BMI: Body Mass Index. Data presented as mean ± standard deviation, (mean and range) or percentage.

Trends in opioids used per case, number of nonopioids per case and patient reported pain scores before and after the intervention are reported in [S1 Table](#pone.0234199.s008){ref-type="supplementary-material"} and [S3](#pone.0234199.s004){ref-type="supplementary-material"}--[S5](#pone.0234199.s006){ref-type="supplementary-material"} Figs. The segmented regression analysis of interrupted time series examining the change in morphine equivalent per case and PACU pain scores before and after the intervention in April 2018 are shown in [Table 2](#pone.0234199.t002){ref-type="table"}, [Fig 3](#pone.0234199.g003){ref-type="fig"} and [Table 3](#pone.0234199.t003){ref-type="table"}, [Fig 4](#pone.0234199.g004){ref-type="fig"} respectively. There was a significant decrease in total (Estimate: -39.9 mg, SE: 6.9 mg, p \< 0.001) and parenteral opioid use (Estimate: -51.6 mg, SE: 7.1 mg, p \< 0.001) after the implementation of the guideline with a significant increase in oral opioid use (Estimate: 9.4 mg, SE: 1.1 mg, p \< 0.001). Furthermore, there is a sustained decrease in total (Estimate: -0.79 mg, SE 0.48 mg, p = 0.11), oral (Estimate: -0.41 mg, SE 0.11 mg, p = 0.001) and parenteral (Estimate: -0.24 mg, SE 0.49 mg, p = 0.64) opioid use following the intervention. Pain scores were not significantly different between the pre and post-intervention period (Estimate: 0.05, SE: 0.13, p = 0.69).

![Interrupted time series with segmented regression analyses demonstrating mean (standard error) total, parenteral and oral morphine equivalents per case by month before and after the intervention.](pone.0234199.g003){#pone.0234199.g003}

![Interrupted time series with segmented regression analyses demonstrating mean (standard error) post anesthesia care unit patient reported pain scores per case by month before and after the intervention.](pone.0234199.g004){#pone.0234199.g004}

10.1371/journal.pone.0234199.t002

###### Full segmented regression models estimating average of morphine equivalent (mg) per case before and after intervention in April, 2018.

![](pone.0234199.t002){#pone.0234199.t002g}

                                        Estimate   SE     *t*     *p*
  ------------------------------------- ---------- ------ ------- ----------
  **Total**                                                       
  Intercept (b0)                        86.5       5.4    16      \< 0.001
  Slope before April, 2018 (b1)         1.3        0.97   1.3     0.21
  Slope change after April, 2018 (b2)   -0.8       0.48   -1.6    0.12
  Level change after April, 2018 (b3)   -39.98     7.0    -5.7    \< 0.001
  **Oral**                                                        
  Intercept (b0)                        1.68       1.1    1.56    0.14
  Slope before April, 2018 (b1)         0.12       0.18   0.69    0.5
  Slope change after April, 2018 (b2)   -0.41      0.11   -3.87   \<0.01
  Level change after April, 2018 (b3)   9.4        1.1    8.9     \< 0.001
  **Parenteral**                                                  
  Intercept (b0)                        84.7       5.5    15.3    \< 0.001
  Slope before April, 2018 (b1)         1.26       0.99   1.26    0.22
  Slope change after April, 2018 (b2)   -0.24      0.49   -0.48   0.64
  Level change after April, 2018 (b3)   -51.56     7.1    -7.25   \< 0.001

The intercept (b0) refers to the level of morphine equivalent use in the first month of the data series (July 2017). b1 refers to the slope of change in morphine equivalent use before April 2018. b2 refers to the difference between slope of change in morphine equivalent use before and after April, 2018, and b3 refers to the change in level of morphine equivalent use after April, 2018. SE: Standard error.

10.1371/journal.pone.0234199.t003

###### Full segmented regression models estimating mean pain scores per case before and after intervention in April, 2018.

![](pone.0234199.t003){#pone.0234199.t003g}

                                        Estimate   SE     *t*    *p*
  ------------------------------------- ---------- ------ ------ ----------
  **Total**                                                      
  Intercept (b0)                        3.79       0.11   35.5   \< 0.001
  Slope before April, 2018 (b1)         -0.01      0.02   -0.7   0.5
  Slope change after April, 2018 (b2)   0.01       0.01   0.6    0.6
  Level change after April, 2018 (b3)   0.05       0.13   0.41   0.69

The intercept (b0) refers to the level of morphine equivalent use in the first month of the data series (July 2017). b1 refers to the slope of change in morphine equivalent use before April 2018. b2 refers to the difference between slope of change in morphine equivalent use before and after April, 2018, and b3 refers to the change in level of morphine equivalent use after April, 2018. SE: Standard error.

The number of nonopioid analgesic medications utilized increased significantly after the intervention (Estimate: 0.9, SE: 0.1, p \< 0.001) ([Table 4](#pone.0234199.t004){ref-type="table"}, [Fig 5](#pone.0234199.g005){ref-type="fig"}). Trends and proportions (% per month and % change from previous month) for individual nonopioids (acetaminophen, celecoxib, dexmedetomidine, esmolol, gabapentin, ketamine and intravenous lidocaine) are represented in [S2 Table](#pone.0234199.s009){ref-type="supplementary-material"} and [S5 Fig](#pone.0234199.s006){ref-type="supplementary-material"}.

![Interrupted time series with segmented regression analyses demonstrating mean (standard error) number of nonopioid analgesics utilized per case by month before and after the intervention.](pone.0234199.g005){#pone.0234199.g005}

10.1371/journal.pone.0234199.t004

###### Full segmented regression models estimating mean number of non-opioid analgesics per case before and after intervention in April, 2018.

![](pone.0234199.t004){#pone.0234199.t004g}

                                        Estimate   SE     *t*     *p*
  ------------------------------------- ---------- ------ ------- ----------
  **Total**                                                       
  Intercept (b0)                        2.29       0.07   35.0    \< 0.001
  Slope before April, 2018 (b1)         0.01       0.01   1.4     0.18
  Slope change after April, 2018 (b2)   -0.01      0.01   -1.45   0.16
  Level change after April, 2018 (b3)   0.9        0.1    10.9    \< 0.001

The intercept (b0) refers to the level of morphine equivalent use in the first month of the data series (July 2017). b1 refers to the slope of change in morphine equivalent use before April 2018. b2 refers to the difference between slope of change in morphine equivalent use before and after April, 2018, and b3 refers to the change in level of morphine equivalent use after April, 2018. SE: Standard error.

Results from a 2-proportions z-test showed no statistically significant difference in the percent of neuraxial or loco-regional procedures performed between the pre (45.4%) and post intervention period (46.6%) \[chi^2^(1) = 3.84, 0.02, p = 0.05\]. The proportion of different neuraxial and loco-regional procedure performed over the study period are represented by the mosaic plot in [S6 Fig](#pone.0234199.s007){ref-type="supplementary-material"} and [S3 Table](#pone.0234199.s010){ref-type="supplementary-material"}. No significant changes, except a reduction in the proportion of both brachial plexus \[Pre: 27 ± 1.9% vs. Post: 25 ± 2.7%, p = 0.04\] and epidural \[Pre: 3.5 ± 0.5% vs. Post: 2.9 ± 0.6%, p = 0.02\] and an increase in femoral blocks \[Pre: 4.4 ± 1.9% vs. Post: 10.0 ± 1.3%, p \< 0.001\] were noted during the study period ([S1 Table](#pone.0234199.s008){ref-type="supplementary-material"}).

Discussion {#sec020}
==========

Our study demonstrates that our Limited Intravenous Opioid Guideline for perioperative pain management is associated with a decrease in total opioid use with equivalent patient reported pain scores in the PACU. Surprisingly, these findings are evident without a significant increase in the number of loco-regional and neuraxial procedures performed in the post-intervention period. This study provides a framework and protocol to manage patients during the pre, intra and immediate postoperative period when supplies of intravenous opioids are limited.

Due to the current opioid epidemic, significant effort has been placed on tightening government regulation on opioid manufacturing by the Drug Enforcement Administration. Concurrently multiple manufacturing violations discovered by the FDA have resulted in significant shortages of intravenous opioids. The unintended consequences of this shortage are the risk of providing sub-standard medical care to patients undergoing surgery and those being treated for chronic cancer pain. There are several ways to mitigate this unpredictable and unreliable intravenous opioid supply chain. In an editorial in the New England Journal of Medicine, Eduardo Bruera suggested some possible solutions including strategic hospital opioid stockpiling and hospital-based compounding of common opioids. \[[@pone.0234199.ref001]\] However, these solutions would be unfeasible within the current federal and state regulatory structure.

An alternate solution, especially for patients being managed in the perioperative period is to optimize nonopioid multi-modal therapy and judicious use of neuraxial and loco-regional techniques. Multiple studies have demonstrated the opioid-sparing effects of acetaminophen and non-steroidal anti-inflammatory agents. \[[@pone.0234199.ref006]--[@pone.0234199.ref009]\] Although the gabapentenoids have reported opioid sparing effects, recent meta-analysis have failed to demonstrate beneficial effect in the perioperative period. \[[@pone.0234199.ref007], [@pone.0234199.ref010]\] However, due to the limited availability of other non-opioid analgesic agents we elected to utilize gabapentenoids for this protocol. Finally, continuous intraoperative use of lidocaine and ketamine infusions has been shown to reduce postoperative pain and opioid use in a variety of surgical procedures. \[[@pone.0234199.ref011], [@pone.0234199.ref012]\] By codifying nonopioid analgesic options and transitioning from parenteral to predominant enteral opioid therapy, we have provided a framework to manage patients undergoing a variety of surgical procedures during periods of limited intravenous opioid availability.

An interesting finding of our study was the significant and sustained decrease in total, intravenous and oral opioid requirements after implementation of the protocol. This effect continued to be evident despite the increasingly availability (February, 2019) of intravenous opioids over the post-intervention period. These findings are similar to the results reported by Ackerman et al. with their experience on an intravenous to oral and subcutaneous substitution policy in a general medical unit. \[[@pone.0234199.ref004]\] They demonstrated that intravenous opioid doses were reduced by 84% (0.06 vs 0.39 doses per patient-day, P \< .001), doses of all parenteral opioids were reduced by 55% (0.18 vs 0.39 doses per patient-day, P \< .001) while mean daily overall opioid exposure decreased by 31% (6.30 \[4.12\] vs 9.11 \[7.34\] MMEs per patient-day). \[[@pone.0234199.ref004]\] Of note, for hospital days 1 through 3, there were no significant postintervention vs. preintervention differences in mean reported pain score for patients receiving opioid therapy: day 1, -0.19 (95% CI, -0.94 to 0.56); day 2, -0.49 (95% CI, -1.01 to 0.03); and day 3, -0.54 (95% CI, -1.18 to 0.09).This finding can be partially explained by the increase use of nonopioid adjuncts in the post-intervention period. Furthermore, there is compelling evidence for the role of intraoperative opioid-induced hyperalgesia increasing postoperative opioid requirements. \[[@pone.0234199.ref013]\] Limiting the dose of intravenous opioids administered potentially reduces the risk of opioid-induced hyperalgesia and therefore patients require less opioids in the postoperative period. However additional, prospective studies are needed to better elucidate this effect. The impact of a sustained prescribing behavioral change amongst our anesthesia providers cannot be under-estimated. Sustainable behavior in the healthcare setting is successful when barriers are limited and when cogent policy changes are mandated, as exemplified by our pragmatic intervention. \[[@pone.0234199.ref014], [@pone.0234199.ref015]\] Finally, our protocol provides a practical framework for perioperative pain management in low and middle income countries where the supply of intravenous opioids is limited or unreliable. \[[@pone.0234199.ref016], [@pone.0234199.ref017]\]

Our study has a significant limitation: the primary aim of this study was to provide a framework to manage patients during the pre, intra and immediate postoperative period, we therefore did not evaluate the impact of our intervention on opioid use and patient reported pain scores after discharge from the PACU. Additional studies are needed to evaluate whether increased use of multi-modal analgesia and a predominant enterally-based opioid analgesic regimen in the immediate perioperative period is associated with reduced hospital and post-discharge opioid requirements. Secondly, dexamethasone was not included as a nonopioid adjunct due to its major benefits confined to pediatric patients undergoing tonsillectomy and as an adjunct to peripheral nerve block procedures. Finally, preoperative pain scores and opioid use were not reliably documented in our electronic medical record and were not included in this study. The impact of the aforementioned factors on postoperative pain and analgesic requirements are well known and is a limitation of this study.

Conclusion {#sec021}
==========

We demonstrate that an enteral based opioid regimen for perioperative analgesia management, anchored by multi-modal nonopioid adjuncts and neuraxial/loco-regional techniques, can mitigate the impact of an intravenous opioid shortage.
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2\. In the ethics statement in the manuscript and in the online submission form, please provide additional information about the patient records used in your retrospective study, including: a) whether all data were fully anonymized before you accessed them; b) the date range (month and year) during which patients\' medical records were accessed; and c) the source of the medical records analyzed in this work (e.g. hospital, institution or medical center name). If patients provided informed written consent to have data from their medical records used in research, please include this information.

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: No

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors report an interesting large cohort study. Due to an unanticipated shortage of intravenous opioids, the authors had to follow the multimodal non-opioid analgesia procedures widely described in the literature. Their results are in line with all the literature. They confirm the potential hyperalgesia induced by opioids.

If the segmented regression analysis is interesting, it remains difficult to follow to be didactic. This aspect needs to be improved.

\+ Give results not only with mean (SE) but also with SD and with median (IQR), Max and Min values.

\+ Has dexamethasone been used in some cases?

\+ Fig 1: summary of ASA classification as not significant; but put the proportions of the different surgeries (not as supplemented data). Is it possible to have the level of preoperative pain, if there is opioid tolerant patient and so (beta-blockers ...)? Differentiate the presentation in tables with a \"classic\" presentation and the figs in trend curves.

\+ What is the possible explanation for a reduced length of time (duration of surgery Vs. duration of anesthesia timing?). A correlation graph between the amount of morphine used during the anesthesia and postoperatively would be useful. A presentation of the potential correlation between postoperative pain and postoperative consumption of morphine would also be useful (in PACU and on the floor). In the same line, can the side effects related to opioids (such as PONV or at least their treatment) and to the molecules used in substitution (such as bradycardia, sedation) be reported? Was there an effect on the length of hospital stay for the same surgical procedure?

\+ Because the intraoperative paradigm shift (opioid-based anesthesia to opioid-reduced anesthesia or opioid-free anesthesia) which reactivity (i.e. pain) monitoring was used during the anesthesia?

Reviewer \#2: In my opinion, an analysis of the non-opioid agents that are used to make morphine sparing is missing. Indeed, the message in the present state is that morphine sparing is mainly a cultural problem and that by using more non-morphine agents the immediate perioperative consumption of morphine is reduced. There is not enough development on the molecules that need to be used more (dexmedetomidine according to your data?). The dose of the drug is not raised, but it is likely that some (such as ketamine) will be used at higher doses, which I think should be said in the discussion.

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Dr Vincent COLLANGE, MD of anesthesiology, Medipole Lyon Villeurbanne, France.

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Response to reviewers

Reviewer \#1: The authors report an interesting large cohort study. Due to an unanticipated shortage of intravenous opioids, the authors had to follow the multimodal non-opioid analgesia procedures widely described in the literature. Their results are in line with all the literature. They confirm the potential hyperalgesia induced by opioids.

If the segmented regression analysis is interesting, it remains difficult to follow to be didactic. This aspect needs to be improved.

\+ Give results not only with mean (SE) but also with SD and with median (IQR), Max and

In the revised manuscript, we included median, minimum, and maximum values in the descriptive statistics (Table 1). We have also provided an additional table (Supplementary Table 1) that reports the mean (standard deviation), median\[interquartile range\] and minimum-maximum for total, parenteral and oral opioids administered as requested by the reviewer. Results of the interrupted time series analyses are presented as means and standard errors (SEs). The SEs reflect the precision of the estimates (i.e., the means). We disagree with this reviewer's suggestion to include standard deviations (SDs), as SDs reflect only the variability of a variable, not the precision of the estimated mean.

\+ Has dexamethasone been used in some cases?

Dexamethasone was not included in this analysis. However, we are aware of several studies that have documented the small but statistically significant reduction in opioid use with dexamethasone. We have included this as a limitation in the 'Discussion'.

\+ Fig 1: summary of ASA classification as not significant; but put the proportions of the different surgeries (not as supplemented data).

We have added the proportions of different surgical services in the manuscript (Fig 2: Proportion of surgical procedures over time)

Is it possible to have the level of preoperative pain, if there is opioid tolerant patient and so (beta-blockers ...)?

Thank you for this insightful comment. Preoperative pain scores were not reliably collected before surgery therefore we did not include them in the analysis. We have added this to the limitations in the 'Discussion' (Page 21, line 354-357).

Differentiate the presentation in tables with a \"classic\" presentation and the figs in trend curves.

In the revised manuscript, we included descriptive statistics by month and additional figures in the supplementary material to illustrate the trends in the data (Supplementary Fig 2-5).

\+ What is the possible explanation for a reduced length of time (duration of surgery Vs. duration of anesthesia timing?).

It's important to differentiate a 'statistically' significant result in such a large dataset vs. the clinically meaningful effect size. The effect size of case length here is 4.5 (1.33) minutes, which is not clinically meaningful in our opinion. This is elaborated in the first paragraph of the Results section.

A correlation graph between the amount of morphine used during the anesthesia and postoperatively would be useful.

We did not parse out the cumulative morphine requirements by pre/intraoperative and post anesthesia care unit. This is primarily due to difficulty in anchoring dose administration for these different time periods due to how they are recorded in the electronic medical record. We therefore did not perform this analysis however we recognize the importance of this analysis.

A presentation of the potential correlation between postoperative pain and postoperative consumption of morphine would also be useful (in PACU and on the floor).

We did not collect any medication data or pain scores from the wards.

In the same line, can the side effects related to opioids (such as PONV or at least their treatment) and to the molecules used in substitution (such as bradycardia, sedation) be reported? Was there an effect on the length of hospital stay for the same surgical procedure?

We did not collect data for complications in this study. Furthermore, the study was confined to the intraoperative and immediate postoperative period only. The primary goal of this study was to present a framework for the use of oral opioids supplemented by nonopioid analgesics in the event of reduced intravenous opioid availability (example during the current COVID pandemic)

\+ Because the intraoperative paradigm shift (opioid-based anesthesia to opioid-reduced anesthesia or opioid-free anesthesia) which reactivity (i.e. pain) monitoring was used during the anesthesia?

The indication for administering intraoperative intravenous opioids are described in the section: Intraoperative Phase of Care (Point 8) on page 9, ln 156-157 and ln 161-162. Primarily hypertension and tachycardia, after excluding inadequate depth of anesthesia, was the trigger to administer intravenous opioids.

Reviewer \#2: In my opinion, an analysis of the non-opioid agents that are used to make morphine sparing is missing.

Thank you for this excellent suggestion. We have provided both a table (Supplementary Table 2) and trend graph of nonopioid analgesics (Supplementary Figure 5) administered during the pre and post-intervention. This provides the reader with information on how the frequency of nonopioid analgesic use changed during the pre and post intervention period.

Indeed, the message in the present state is that morphine sparing is mainly a cultural problem and that by using more non-morphine agents the immediate perioperative consumption of morphine is reduced.

We humbly disagree with the reviewer on this point. We feel that there are two factors at play: increased nonopioid use (on average one additional nonopioid use) and the phenomena of reduced opioid induced hyperalgesia with less total intraoperative opioid used, as highlighted by reviewer 1.

There is not enough development on the molecules that need to be used more (dexmedetomidine according to your data?). The dose of the drug is not raised, but it is likely that some (such as ketamine) will be used at higher doses, which I think should be said in the discussion.

We have provided an ITS on the number of nonopioid analgesics administered during the case. Per the reviewer's earlier suggestion, we have provided both a table and trend graph of nonopioid analgesics administered during the pre and post-intervention. This provides the reader with data on how the frequency of nonopioid analgesic use changed during the pre and post intervention period. Doses of medications were not changed during the post intervention period.
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PLOS ONE

Dear Dr. Naik,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the last point raised during the review process.

Please consider the reviewer\'s comment and amend your discussion accordingly: \"The modifications with the non-opioid molecules may have been introduced before the change in practice or without any change. This could only partially be due to the change in the route of administration of opioids.\"

Please consider the \"minor points\" too.

We would appreciate receiving your revised manuscript by Jul 03 2020 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to the point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Patrice Forget

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Partly

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: I Don\'t Know

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: I carefully reread the revised version of the manuscript, the questions and the answers. I am perplexed about the didactic interest of this work. Indeed, if the evolution was made due to a restriction of the parenteral opioid stock, it also corresponds to the classic evolution of practices with a more extensive use of non-opioid analgesic drugs. This current work confirms these results: more non-opioid used allows less opioid for, at least, the same effectiveness. If we look carefully at the modifications with the non-opioid molecules; it seems to have been introduced before the change in practice (see: dexmedetomidine, acetaminophen and celecoxib) or without any change (lidocaine, esmolol). Would this be due only to the change in the route of administration of opioids (i.e. oral Vs. parenteral)? I'm not so sure.

Minor points.

\+ The use of gabapentin preoperatively is less and less recommended on the basis of meta-analysis.

\+ P7 L1119-120 "prior to surgery, add during the procedure, and in the PACU"

\+ Can\'t the fact that the patients were significantly older, with significantly shorter procedures, be responsible for these results?

Reviewer \#2: (No Response)

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Vincent Collange MD, Anesthesiology, Medipole Lyon Villeurbanne

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Reviewer \#1:

I carefully reread the revised version of the manuscript, the questions and the answers. I am perplexed about the didactic interest of this work. Indeed, if the evolution was made due to a restriction of the parenteral opioid stock, it also corresponds to the classic evolution of practices with a more extensive use of non-opioid analgesic drugs. This current work confirms these results: more non-opioid used allows less opioid for, at least, the same effectiveness.

Response: We agree with the reviewer that increased nonopioid analgesic use (based on a protocol) definitely has an opioid sparing effect. This study confirms this well described effect. However, the study also elucidates the comparative benefits of an oral opioid regimen that can be utilized when parenteral opioids are limited. Furthermore, our study also tentatively explores the effect of opioid induced hyperalgesia caused by high dose parenteral opioids, which may be mitigated by oral opioids. This is reported extensively in the 'Discussion' section.

If we look carefully at the modifications with the non-opioid molecules; it seems to have been introduced before the change in practice (see: dexmedetomidine, acetaminophen and celecoxib) or without any change (lidocaine, esmolol).

Response: The changes in nonopoid use varied slightly between agents but Supplementary table 2 clears demonstrates the % changes when the protocol was formally started in April, 2018 compared to the previous month\[Acetaminophen (54 to 72%), celecoxib (13 to 18-28%), dexmedetomidine (31 to 45%).

Would this be due only to the change in the route of administration of opioids (i.e. oral Vs. parenteral)? I'm not so sure.

Response: Our study tentatively explores the effect of opioid induced hyperalgesia caused by high dose parenteral opioids, which may be mitigated by oral opioids. We discuss the findings of the study by Ackerman et al who demonstrated reduced opioid use when they transitioned from a parenteral to oral opioid regimen (Page 20, line 331-345). This is reported extensively in the 'Discussion' section.

Minor points.

\+ The use of gabapentin preoperatively is less and less recommended on the basis of meta-analysis.

Response: We agree with the reviewer and have included this in our Discussion (Page 20, line 318-321)

\+ P7 L1119-120 "prior to surgery, add during the procedure, and in the PACU"

Response: We have added this to the manuscript. Page 7, line 120-121

\+ Can\'t the fact that the patients were significantly older, with significantly shorter procedures, be responsible for these results?

Response: We humbly disagree with the reviewer for the following reasons: 1) the cohort size for this study is large (n=29, 621), therefore small changes may be statistically significant. However, it is important to interpret the effect size of the change in age and procedure length, which is included in Table 1. The effect size for age is 0.61 years, while the procedure length is 4.49 minutes. These changes are not clinically relevant. The following reference is critical to understanding our response : Using Effect Size---or Why the P Value Is Not Enough.

J Grad Med Educ. 2012 Sep; 4(3): 279--282. PMID: 23997866. We have addressed this on page 12, line 217-221.
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Dear Dr. Naik,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Patrice Forget

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:
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Impact of A Perioperative Oral Opioid Substitution Protocol During The Nationwide Intravenous Opioid Shortage: A Single Center, Interrupted Time Series with Segmented Regression Analysis

Dear Dr. Naik:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Prof. Patrice Forget

Academic Editor

PLOS ONE
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